Pruritus in primary myelofibrosis: Clinical and laboratory correlates

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 136-138

  Vaa, Brianna E ^a   Wolanskyj, Alexandra P ^b   Roeker, Lindsey ^a   Pardanani, Animesh ^b   Lasho, Terra L ^b   Finke, Christy M ^b   Tefferi, Ayalew ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; MALE; MEDICAL HISTORY; MYELOID METAPLASIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RISK; SURVIVAL; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FEMALE; HUMANS; JANUS KINASE 2; KARYOTYPING; LEUKOCYTOSIS; LEUKOPENIA; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PRURITUS; RECEPTORS, THROMBOPOIETIN;

EID: 84855962812     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22215     Document Type: Article

References (20)

1. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 2010; 40: 828-834.
2. Diehn F, Tefferi A. Pruritus in polycythaemia vera: Prevalence, laboratory correlates and management. Br J Haematol 2001; 115: 619-621.
3. Gangat N, Strand JJ, Lasho TL, et al. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol 2008; 83: 451-453.
4. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-846.
5. Pieri L, Bogani C, Guglielmelli P, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 2009; 94: 1537-1545.
6. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
7. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. Blood 1966; 28: 795-806.
8. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients. Cancer 2007; 109: 68-76.
9. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320-328.
10. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030-4036.
11. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
12. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
13. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446-455.
14. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118: 2069-2076.
15. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
16. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
17. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
18. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
19. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
20. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131-1136.